Nasal Polyposis - Epidemiology Forecast - 2032

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,950	79 Pages	DelveInsight	February, 2022	DEL16978081

Best Price Guarantee
Price	from $3,950
Length	79 Pages
Publisher	DelveInsight
Published Date	February, 2022
SKU	DEL16978081

DelveInsight’s "Nasal Polyposis (NP)- Epidemiology Forecast–2032" report delivers an in-depth understanding of the Nasal Polyposis, historical and forecasted epidemiology as well as the Nasal Polyposis epidemiology trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Nasal Polyposis (NP) Disease Understanding
Nasal polyposis (NP) is small, benign (Noncancerous) drop-like growths appearing in the mucosa (lining tissues) of the nose and may block the nasal passageway. Nasal polyposis tends to be present on both sides of the nasal cavity. Small nasal polyps may not reflect any symptoms, but the larger growths or groups of nasal polyps can block the nasal passages or lead to breathing problems, a lost sense of smell, and frequent infections. One-sided nasal polyps may need to be investigated further as they might be malignant nasal or sinus tumors. Nasal polyps are a subgroup of chronic rhinosinusitis (CRS). CRS is a condition where the nasal cavity and sinuses are inflamed for more than 4 to 12 weeks. Patients suffering from CRS condition can be progressed into chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic rhinosinusitis without nasal polyposis (CRSsNP). Only a portion of CRS will develop nasal polyposis.
CRSwNP is a potentially debilitating condition in adults that are characterized by inflammation of the nose and paranasal sinuses with the presence of nasal polyps. People with a history of chronic sinus infections, allergic rhinitis, asthma, cystic fibrosis, sensitivity to NSAIDs like ibuprofen and aspirin, and Churg–Strauss syndrome are more prone to get NP.
Patients suffering from NP may experience chronic nasal congestion, running nose, postnasal drip, reduced sense of smell and taste, difficulty in breathing, pressure in the face or forehead area, snoring, sleep apnea, and others.
Nasal Polyposis (NP) Diagnosis
For the diagnosis of nasal polyps, an ENT specialist or any other physician first look into nasal passages with a special lighted instrument known as a nasoscope. The most preferred techniques are confirming the location, size, and severity of polyps nasal endoscopy, and radiological imaging. Further allergy tests and blood tests can be done to determine other disease-related components.
Continued in the report…..
Nasal Polyposis (NP) Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of chronic rhinosinusitis (CRS), diagnosed prevalent cases of chronic rhinosinusitis, diagnosed prevalent cases of nasal polyposis, and gender-specific diagnosed prevalent cases of nasal polyposis scenario of Nasal Polyposis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.
Nasal Polyposis Detailed Epidemiology Segmentation
• Total prevalent cases of Chronic Rhinosinusitis (CRS) in the 7MM were found to be 69,550,461 in 2021, which are expected to increase at a Compound Annual Growth Rate (CAGR) of 0.44% during the study period.
• The diagnosed prevalent cases of CRS in the 7MM were found to be 17,973,714 in 2021, which are expected to increase at a CAGR of 0.48% for the study period of 2019-2032.
• As per DelveInsight’s estimates, 7MM accounts for 4,358,603 diagnosed prevalent cases of nasal polyposis in 2021, which are expected to increase at a CAGR of 0.50%.
• Among 7MM, the United States has the highest diagnosed cases of nasal polyposis with 2,172,969 cases in 2021. Among these cases, 55% of cases were male (1,195,133 cases).
• In 2021, EU-5 accounts for 1,982,824 diagnosed prevalent cases of nasal polyposis, which might increase by 2032 at a CAGR of 0.24%.
• In EU-5, Germany had the highest diagnosed cases of nasal polyposis with 617,716 cases, followed by the UK with 435,157 cases and France with 432,058 cases, in 2021. While Spain had the least number of cases with 187,246 in 2021.
• In 2021, Japan had 202,810 diagnosed cases of nasal polyposis ranking second-lowest among 7MM. These cases are expected to decrease by 2032 at a CAGR of -0.28% due to decreasing adult population in the country during the forecasted period (2022–2032).
Scope of the Report
• The report covers the descriptive overview of Nasal Polyposis, explaining its symptoms, etiology, pathogenesis, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden of Nasal Polyposis.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM total prevalent cases of chronic rhinosinusitis, diagnosed prevalent cases of chronic rhinosinusitis, diagnosed prevalent cases of nasal polyposis, and gender-specific diagnosed prevalent cases of nasal polyposis.

Report Highlights
• 11-Year Forecast of Nasal Polyposis
• 7MM Coverage
• Total Prevalent Cases of Chronic Rhinosinusitis
• Diagnosed Prevalent Cases of Chronic Rhinosinusitis
• Diagnosed Prevalent Cases of Nasal Polyposis
• Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis
Key Questions Answered
• What are the disease risk and burdens of Nasal Polyposis (NP)?
• What is the historical Nasal Polyposis (NP) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Nasal Polyposis (NP) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Nasal Polyposis (NP)?
• Out of the above-mentioned countries, which country would have the highest patient population of Nasal Polyposis (NP) during the forecast period (2022–2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?
Reasons to buy
The Nasal Polyposis (NP) report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM Nasal Polyposis (NP) epidemiology forecast.
• The Nasal Polyposis (NP) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Nasal Polyposis (NP) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.
Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2019–2032

1. Key Insights
2. Report Introduction
3. Nasal Polyposis Epidemiology Overview at a Glance: 3.1. Patient Share (%) Distribution of Nasal Polyposis in 2019; 3.2. Patient Share (%) Distribution of Nasal Polyposis in 2032
4. Executive Summary of Nasal Polyposis
5. Disease Background and Overview: Nasal Polyposis: 5.1. Introduction; 5.2. Signs and Symptoms; 5.3. Etiology; 5.4. Causes; 5.5. Pathogenesis; 5.6. Diagnostic Approach; 5.6.1. JESREC Score Criteria for the Diagnosis of Eosinophilic Chronic Rhinosinusitis; 5.6.2. Diagnostic Algorithm
6. Epidemiology and Patient Population: 6.1. Key Findings; 6.2. Methodology of Epidemiology; 6.3. Assumptions and Rationale: 7MM; 6.3.1. The United States; 6.3.2. Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom); 6.3.3. Japan; 6.4. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the 7MM; 6.5. Total Diagnosed Prevalent Cases of Nasal Polyposis in the 7MM; 6.6. The United States; 6.6.1. Prevalent Cases of Chronic Rhinosinusitis in the United States; 6.6.2. Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the United States; 6.6.3. Diagnosed Prevalent Cases of Nasal Polyposis in the United States; 6.6.4. Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in the United States; 6.7. EU-5; 6.7.1. Prevalent Cases of Chronic Rhinosinusitis in the EU-5; 6.7.2. Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the EU-5; 6.7.3. Diagnosed Prevalent Cases of Nasal Polyposis in the EU-5; 6.7.4. Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in the EU-5; 6.8. Japan; 6.8.1. Prevalent Cases of Chronic Rhinosinusitis in Japan; 6.8.2. Diagnosed Prevalent Cases of Chronic Rhinosinusitis in Japan; 6.8.3. Diagnosed Prevalent Cases of Nasal Polyposis in Japan; 6.8.4. Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in Japan
7. Patient Journey
8. KOL Views: 8.1. United States; 8.2. EU-5; 8.3. Japan
9. Appendix: 9.1. Bibliography; 9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight: Table 1: Summary of Nasal Polyposis Epidemiology (2019–2032); Table 2: JESREC score criteria for the diagnosis of eosinophilic chronic rhinosinusitis; Table 3: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the 7MM, in ‘000’ (2019–2032); Table 4: Total Diagnosed Prevalent Cases of Nasal Polyposis in the 7MM, in ‘000’ (2019–2032); Table 5: Prevalent Cases of Chronic Rhinosinusitis in the United States, in ‘000’ (2019–2032); Table 6: Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the US, in ‘000’ (2019–2032); Table 7: Diagnosed Prevalent Cases of Nasal Polyposis in the US, in ‘000’ (2019–2032); Table 8: Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in the US, in ‘000’ (2019–2032); Table 9: Prevalent Cases of Chronic Rhinosinusitis in the EU-5, in ‘000’ (2019–2032); Table 10: Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the EU-5, in ‘000’ (2019–2032); Table 11: Diagnosed Prevalent Cases of Nasal Polyposis in the EU-5, in ‘000’ (2019–2032); Table 12: Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in the EU-5, in ‘000’ (2019–2032); Table 13: Prevalent Cases of Chronic Rhinosinusitis in Japan, in ‘000’ (2019–2032); Table 14: Diagnosed Prevalent Cases of Chronic Rhinosinusitis in Japan, in ‘000’ (2019–2032); Table 15: Diagnosed Prevalent Cases of Nasal Polyposis in Japan, in ‘000’ (2019–2032); Table 16: Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in Japan, in ‘000’ (2019–2032)Figure 1: Nasal polyps in the nose and sinus cavity; Figure 2: Anatomy of normal nasal area vs. Chronic Rhinosinusitis with Nasal Polyposis; Figure 3: Radiographic findings in severe Chronic Rhinosinusitis with Nasal Polyposis; Figure 4: Primary symptoms of Nasal polyps; Figure 5: Secondary symptoms of Nasal polyps; Figure 6: Etiology of Nasal Polyps; Figure 7: Causes of Nasal Polyps; Figure 8: Hypothetical timeline and interactions of events in the formation of nasal polyps; Figure 9: Differential diagnosis of nasal polyps; Figure 10: Diagnostic algorithm of refractory chronic rhinosinusitis; Figure 11: Four-step diagnosis of sinonasal disorders; Figure 12: Diagnostic-therapeutic Algorithm in Nasal Polyposis; Figure 13: Prognostic index of nasal polyp relapse based on clinical and cytologic grading; Figure 14: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the 7MM, in ‘000’ (2019–2032); Figure 15: Total Diagnosed Prevalent Cases of Nasal Polyposis in the 7MM, in ‘000’ (2019–2032); Figure 16: Prevalent Cases of Chronic Rhinosinusitis in the United States, in ‘000’ (2019–2032); Figure 17: Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the US, in ‘000’ (2019–2032); Figure 18: Diagnosed Prevalent Cases of Nasal Polyposis in the US, in ‘000’ (2019–2032); Figure 19: Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in the US, in ‘000’ (2019–2032); Figure 20: Prevalent Cases of Chronic Rhinosinusitis in the EU-5, in ‘000’ (2019–2032); Figure 21: Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the EU-5, in ‘000’ (2019–2032); Figure 22: Diagnosed Prevalent Cases of Nasal Polyposis in the EU-5, in ‘000’ (2019–2032); Figure 23: Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in the EU-5, in ‘000’ (2019–2032); Figure 24: Prevalent Cases of Chronic Rhinosinusitis in Japan, in ‘000’ (2019–2032); Figure 25: Diagnosed Prevalent Cases of Chronic Rhinosinusitis in Japan, in ‘000’ (2019–2032); Figure 26: Diagnosed Prevalent Cases of Nasal Polyposis in Japan, in ‘000’ (2019–2032); Figure 27: Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in Japan, in ‘000’ (2019–2032); Figure 28: Patient Journey